-
the way to break the drug resistance| review of the annual progress of breast cancer treatment in 2022
Time of Update: 2023-02-01
On January 7, 2023, the "2022 Annual Progress Review of Breast Cancer Treatment", a grand event in the field of breast cancer, opened in Beijing. The conference reviewed the important academic progres
-
Transl Res: Major advances in concomitant diagnostics with targeted drugs for lung cancer
Time of Update: 2023-01-04
Enrichment of EGFR Sub-Del library mutants and EGFR Ins-1 library variants for the cytotoxicity of five TKIsIn summary, the sensitivity of relevant mutations to five first-line EGFR-TKI-targeted drugs was evaluated by systematic drug sensitivity screening experiments for 7,4389 rare variants of EGFR gene in lung cancer.
-
HER2 exon 20 inserted mutation lung cancer (NSCLC) innovative drug! Pan-HER tyrosine kinase
Time of Update: 2023-01-01
The NDA seeks approval for poziotinib: a novel, oral, irreversible EGFR family receptor-blocking pan-HER inhibitor for the treatment of previously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying HER2 exon 20 insertion mutations (Ex20ins).
-
First to be confirmed: an epigenetic drug EZH2 inhibitor that treats bladder cancer by activating the immune system
Time of Update: 2022-10-21
The study is the first to confirm that Tazemetostat, an epigenetic drug currently used to treat lymphoma and sarcoma, is able to suppress bladder cancer by activating the immune system。 The research team has initiated human clinical trials for advanced bladder cancer.
-
Can ACE inhibitors/ARB antihypertensive drugs prevent cardiotoxicity caused by chemotherapy in early breast cancer?
Time of Update: 2022-10-19
A meta-analysis published in the journal Transl Cancer Res evaluated the effect of ACE inhibitors/ARBs on cardiotoxicity induced by anthracycline chemotherapy with or without trastuzumab in patients with early-stage breast cancer。 ACEI and ARB have a definite antihypertensive effect, especially in patients with heart failure, myocardial infarction, diabetes, and chronic kidney disease, and there is sufficient evidence to improve prognosis.
-
Science Advances: First confirmed: epigenetic drug EZH2 inhibitors, which treat bladder cancer by activating the immune system
Time of Update: 2022-10-12
Next, the team used the commercially available EZH2 inhibitor Tazemetostat to treat mice with bladder cancer, and the results showed that tazestat filled the bladders of mice with immune cells.
-
【Cell】 Shi Hubing/Jingjing team of West China Hospital revealed the drug resistance mechanism of triple-negative breast cancer to MEK inhibitors
Time of Update: 2022-10-02
On September 12, a team led by Professor Shi Hubing of the State Key Laboratory of Biotherapy at West China Hospital of Sichuan University and Professor Jing Jing of West China Hospital of Sichuan University published an article entitled "PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in" in Cell Reports Medicine triple-negative breast cancer" research paper.
-
Major milestone: The third-generation ALK inhibitor lorlatinib, an innovative lung cancer drug, was approved in China
Time of Update: 2022-05-22
On April 29 , 2022 , Pfizer announced that the world's first third-generation ALK inhibitor Borrena® ( Lorbrena® , generic name: Lorlatinib Tablets ) was approved by the State Drug Administration for single drug use for the treatment of patients with anaplastic lymphoma kinase ( ALK )-positive locally advanced or metastatic non-small cell lung cancer ( NSCLC ) .
-
[Nature sub-issue] Too cunning, "anti-cancer magic drug" PARP inhibitor can also allow cancer cells
Time of Update: 2022-01-24
Excitingly, this study shows that drugs currently used to treat alcohol addiction can be combined with PARP inhibitors to make the treatment of breast cancer caused by a mutated BRCA gene more effective .
-
Immunologic drugs help first-line treatment benefits for patients with advanced colorectal cancer, domestic PD-L1 inhibitors bring new treatment options
Time of Update: 2021-12-29
In the pivotal phase II study of envolimab [2], the objective response rate of envolimab as a single agent (administered at 150 mg QW) for 65 patients with MSI-H/dMMR colorectal cancer as second-line treatment (ORR) is 43.
-
Preliminary exploration of new drugs: How effective are GLS inhibitors in treated renal cancer?
Time of Update: 2021-10-02
The CANTATA study explored the efficacy and safety of Telaglenastat+Cabotinib versus placebo+Cabotinib in patients with treated metastatic clear cell renal cell carcinoma (NCT03428217) .
In the placebo+cabotinib group, the median PFS of patients who received immunotherapy was 9.
-
Sihuan Pharmaceutical's Class 1 new drug CDK4/6 inhibitor approved for Phase III clinical treatment of breast cancer
Time of Update: 2021-08-28
It is also the malignant tumor with the highest incidence of women in the world, and about 680,000 patients died of breast cancer .
-
Inhibitor drug entinostat "stimulates" the body's immune response against cancer
Time of Update: 2021-08-26
Rusos Torres, MD, PhD, adjunct professor at Johns Hopkins University and assistant professor of medicine at the University of Southern California Norris Comprehensive Cancer Center in Los Angeles, at Before immunotherapy for solid tumors that traditionally did not respond to checkpoint suppression therapy, entinostat acted as an immune system priming agent .
-
Changes in the drug market for advanced prostate cancer: AR and PARP inhibitor market expands, PSMA potential increases
Time of Update: 2021-08-08
Among them, the use of traditional castration therapy ADT will be reduced, with the blockbuster drug Zytiga (Abiraterone acetate) and Xtandi (Enzalutamide)-based androgen receptor (AR) antagonists have overturned the treatment pattern of metastatic prostate cancer, the market share will continue to increase, PARP inhibitors and PSMA radiation Ligand therapy has a chance to gain a place, and kinase inhibitors, including Akt inhibitors, will also have an effect on subdivided groups .
-
New drug approved in May | Domestic PARP inhibitors launched, new first-line treatment for HER2-positive gastric cancer
Time of Update: 2021-05-22
Pamiparib May 7, 2021 Beijing time, the China National Medical Products Administration (NMPA) conditionally approved the PARP inhibitor Pamipa for use in the treatment of at least two lines of chemotherapy in the past, accompanied by germline BRCA (gBRCA) Patients with mutated advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.